We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Erytech Pharma SA (ERYP) EUR0.1

Sell:€2.03 Buy:€2.04 Change: €0.03 (1.46%)
Prices delayed by at least 15 minutes | Switch to live prices |
Change: €0.03 (1.46%)
Prices delayed by at least 15 minutes | Switch to live prices |
Change: €0.03 (1.46%)
Prices delayed by at least 15 minutes | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Erytech Pharma SA, also known as ERYTECH Pharma, is a France-based biopharmaceutical company developing medicinal products mainly in oncology, hematology and immunology fields of business. The Company offers ESY-ASP (GRASPA), a medicinal product consisting of L-Asparaginase entrapped into human homologous red blood cells. The product is used for treatment of Acute Lymphoblastic Leukemia (ALL), a childhood cancer. The Company's technology is based on the use of human red blood cells (RBCs) to improve the pharmacokinetic (PK) and pharmacodynamic (PD) properties of therapeutic enzymes, for instance asparaginase. The enzyme can destroy asparagine and deprive cancer cells of an important nutrient for these cells, resulting in their death.

Contact details

60 avenue Rockefeller, Batiment Adenine
+33 (4) 78744438

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
€63.74 million
Shares in issue:
26.44 million
Euronext Paris

Key personnel

  • Gil Beyen
    Chief Executive Officer, Director
  • Eric Soyer
    Chief Financial Officer, Chief Operating Officer, Executive Director
  • Stewart Craig
    Chief Technology Officer
  • Francoise Horand-Phothirath
    Director of Research & Development Operations
  • Anne-cecile Fumey
    Human Resources Director
  • Jerome Bailly
    Director of Pharmaceutical Operations and Qualified Person
  • Jean-Sebastien Cleiftie
    Chief Business Officer
  • Iman El-Hariry
    Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.